{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T18:22:20Z","timestamp":1770834140902,"version":"3.50.1"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2004,5,20]],"date-time":"2004-05-20T00:00:00Z","timestamp":1085011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"International Society for Biological Therapy of Cancer"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,5,20]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Immunotherapy using adoptive cell transfer is a promising approach that can result in the regression of bulky, invasive cancer in some patients. However, currently available therapies remain less successful than desired. To study the mechanisms of action and possible improvements in cell-transfer therapies, we use a murine model system with analogous components to the treatment of patients. T cell receptor transgenic CD8+ T cells (pmel-1) specifically recognizing the melanocyte differentiation antigen gp100 are adoptively transferred into lympho-depleted mice bearing large, established, 14-day subcutaneous B16 melanoma (0.5\u20131 cm in diameter) on the day of treatment. Adoptive cell transfer in combination with interleukin interleukin-2 or interleukin-15 cytokine administration and vaccination using an altered form of the target antigen, gp100, can result in the complete and durable regression of large tumor burdens. Complete responders frequently develop autoimmunity with vitiligo at the former tumor site that often spreads to involve the whole coat. These findings have important implications for the design of immunotherapy trials in humans.<\/jats:p>","DOI":"10.1189\/jlb.0304120","type":"journal-article","created":{"date-parts":[[2004,5,25]],"date-time":"2004-05-25T00:38:44Z","timestamp":1085445524000},"page":"333-337","source":"Crossref","is-referenced-by-count":40,"title":["Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer"],"prefix":"10.1093","volume":"76","author":[{"given":"Steven E","family":"Finkelstein","sequence":"first","affiliation":[{"name":"National Cancer Institute, National Institutes of Health, Surgery Branch , Bethesda, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David M","family":"Heimann","sequence":"additional","affiliation":[{"name":"National Cancer Institute, National Institutes of Health, Surgery Branch , Bethesda, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher A","family":"Klebanoff","sequence":"additional","affiliation":[{"name":"National Cancer Institute, National Institutes of Health, Surgery Branch , Bethesda, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul A","family":"Antony","sequence":"additional","affiliation":[{"name":"National Cancer Institute, National Institutes of Health, Surgery Branch , Bethesda, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Gattinoni","sequence":"additional","affiliation":[{"name":"National Cancer Institute, National Institutes of Health, Surgery Branch , Bethesda, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian S","family":"Hinrichs","sequence":"additional","affiliation":[{"name":"National Cancer Institute, National Institutes of Health, Surgery Branch , Bethesda, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leroy N","family":"Hwang","sequence":"additional","affiliation":[{"name":"National Cancer Institute, National Institutes of Health, Surgery Branch , Bethesda, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas C","family":"Palmer","sequence":"additional","affiliation":[{"name":"National Cancer Institute, National Institutes of Health, Surgery Branch , Bethesda, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul J","family":"Spiess","sequence":"additional","affiliation":[{"name":"National Cancer Institute, National Institutes of Health, Surgery Branch , Bethesda, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah R","family":"Surman","sequence":"additional","affiliation":[{"name":"National Cancer Institute, National Institutes of Health, Surgery Branch , Bethesda, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Wrzesiniski","sequence":"additional","affiliation":[{"name":"National Cancer Institute, National Institutes of Health, Surgery Branch , Bethesda, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiya","family":"Yu","sequence":"additional","affiliation":[{"name":"National Cancer Institute, National Institutes of Health, Surgery Branch , Bethesda, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven A","family":"Rosenberg","sequence":"additional","affiliation":[{"name":"National Cancer Institute, National Institutes of Health, Surgery Branch , Bethesda, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas P","family":"Restifo","sequence":"additional","affiliation":[{"name":"National Cancer Institute, National Institutes of Health, Surgery Branch , Bethesda, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2004,5,20]]},"reference":[{"key":"2023033100015020000_","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3322\/canjclin.54.1.8","article-title":"Cancer statistics, 2004","volume":"54","author":"Jemal","year":"2004","journal-title":"CA Cancer J. Clin."},{"key":"2023033100015020000_","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.1200\/JCO.2001.19.16.3622","article-title":"Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system","volume":"19","author":"Balch","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"2023033100015020000_","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.1996.14.1.7","article-title":"Interferon-\u03b1-2b adjuvant therapy of high risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group trial EST 1684","volume":"14","author":"Kirkwood","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"2023033100015020000_","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1200\/JCO.2000.18.22.3782","article-title":"Prognostic factors in metastatic melanoma: a pooled analysis of Eastern Cooperative Oncology Group trials","volume":"18","author":"Manola","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"2023033100015020000_","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","article-title":"High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993","volume":"17","author":"Atkins","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"2023033100015020000_","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1126\/science.1076514","article-title":"Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes","volume":"298","author":"Dudley","year":"2002","journal-title":"Science"},{"key":"2023033100015020000_","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/nrc1167","article-title":"Adoptive-cell-transfer therapy for the treatment of patients with cancer","volume":"3","author":"Dudley","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"2023033100015020000_","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1074-7613(00)80028-X","article-title":"A new era for cancer immunotherapy based on the genes that encode cancer antigens","volume":"10","author":"Rosenberg","year":"1999","journal-title":"Immunity"},{"key":"2023033100015020000_","first-page":"1636","article-title":"In vitro selection of murine B16 melanoma variants with enhanced tissue- invasive properties","volume":"40","author":"Poste","year":"1980","journal-title":"Cancer Res."},{"key":"2023033100015020000_","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1073\/pnas.90.8.3539","article-title":"Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity","volume":"90","author":"Dranoff","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2023033100015020000_","first-page":"1095","article-title":"Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells","volume":"61","author":"Seliger","year":"2001","journal-title":"Cancer Res."},{"key":"2023033100015020000_","doi-asserted-by":"crossref","first-page":"6458","DOI":"10.1073\/pnas.91.14.6458","article-title":"Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection","volume":"91","author":"Kawakami","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2023033100015020000_","doi-asserted-by":"crossref","first-page":"29198","DOI":"10.1016\/S0021-9258(19)62030-2","article-title":"The Pmel 17\/silver locus protein. Characterization and investigation of its melanogenic function","volume":"269","author":"Kobayashi","year":"1994","journal-title":"J. Biol. Chem."},{"key":"2023033100015020000_","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/00002371-199701000-00002","article-title":"Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100","volume":"20","author":"Zhai","year":"1997","journal-title":"J. Immunother."},{"key":"2023033100015020000_","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1084\/jem.188.2.277","article-title":"gp100\/pmel 17 is a murine tumor rejection antigen: induction of \u201cself\u201d-reactive, tumoricidal T cells using high-affinity, altered peptide ligand","volume":"188","author":"Overwijk","year":"1998","journal-title":"J. Exp. Med."},{"key":"2023033100015020000_","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1084\/jem.20030590","article-title":"Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells","volume":"198","author":"Overwijk","year":"2003","journal-title":"J. Exp. Med."},{"key":"2023033100015020000_","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1073\/pnas.0307298101","article-title":"IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells","volume":"101","author":"Klebanoff","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2023033100015020000_","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/00002371-199601000-00009","article-title":"Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy","volume":"19","author":"Rosenberg","year":"1996","journal-title":"J. Immunother. Emphasis Tumor Immunol."},{"key":"2023033100015020000_","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1084\/jem.192.11.1637","article-title":"Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of T cell-mediated vitiligo","volume":"192","author":"Yee","year":"2000","journal-title":"J. Exp. Med."},{"key":"2023033100015020000_","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1172\/JCI0217214","article-title":"Adoptive therapy with CD8 + T cells: it may get by with a little help from its friends","volume":"110","author":"Ho","year":"2002","journal-title":"J. Clin. Invest."},{"key":"2023033100015020000_","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/00002371-200205000-00002","article-title":"Do CD4 + CD25+ immunoregulatory T cells hinder tumor immunotherapy?","volume":"25","author":"Antony","year":"2002","journal-title":"J. Immunother."}],"container-title":["Journal of Leukocyte Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1189%2Fjlb.0304120","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jleukbio\/article-pdf\/76\/2\/333\/49654347\/jlb0333.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jleukbio\/article-pdf\/76\/2\/333\/49654347\/jlb0333.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T18:38:42Z","timestamp":1682707122000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jleukbio\/article\/76\/2\/333\/6926272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5,20]]},"references-count":21,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2004,5,20]]},"published-print":{"date-parts":[[2004,5,20]]}},"URL":"https:\/\/doi.org\/10.1189\/jlb.0304120","relation":{},"ISSN":["0741-5400","1938-3673"],"issn-type":[{"value":"0741-5400","type":"print"},{"value":"1938-3673","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2004,8]]},"published":{"date-parts":[[2004,5,20]]}}}